Researchers are testing the effectiveness of Metformin to help improve daily living for individuals with Fragile X syndrome.
The trial further assesses Metformin’s safety, as well as the benefits of the drug, which has been shown to improve the symptoms and difficulties individuals with FXS experience, including: delayed language/cognition, excessive eating, obesity, hypogonadism, and delayed puberty.
Who can participate?
Individuals aged 6–25 who have been diagnosed with FXS (and who fit the inclusion/exclusion criteria).
What will happen in the study?
Commit to a four-month study which includes three clinic visits, and five phone calls while taking Metformin orally. Complete various tasks, questionnaires, and examinations by a physician/research team, as well as have blood drawn, as well as urine and stool samples taken.
Will you/your child be paid to complete this survey?
Travel expenses will be reimbursed.
Study doctors and locations
Please fill out the form below to send your contact information to the study coordinators.
Dr. Francois Bolduc, Principal Investigator
University of Alberta/Stollery Children’s Hospital
Edmonton, Alberta, Canada
Clinical Research Coordinator: Call (780) 492-9461 or email
Dr. Sébastien Jacquemont, Principal Investigator
CHU Ste. Justine
Montreal, Quebec, Canada
Study Coordinators: Maryse Thibeault or Sophie Morin